Dr. Ott is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Dana 2127
Boston, MA 02215Phone+1 617-582-9030Fax+1 212-263-6727
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2005 - 2008- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2007
Ludwig Maximilian University of Munich Faculty of MedicineClass of 1996
Certifications & Licensure
FL State Medical License 2022 - Present
MA State Medical License 2012 - 2026
NY State Medical License 2008 - 2013
OH State Medical License 2002 - 2005
Clinical Trials
- A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma Start of enrollment: 2014 Jan 01
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors Start of enrollment: 2013 Nov 15
- Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma Start of enrollment: 2014 May 01
- Join now to see all
Publications & Presentations
PubMed
- 43 citationsTargeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomasJonathan J. Lee, Lynette M. Sholl, Neal I. Lindeman, Scott R. Granter, Alvaro C. Laga
Clinical Epigenetics. 2015-06-09 - 362 citationsPhase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF InhibitorKevin B. Kim, Richard F. Kefford, Anna C. Pavlick, Jeffrey R. Infante, Antoni Ribas
Journal of Clinical Oncology. 2013-02-01 - 295 citationsPharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic MelanomaKerstin Trunzer, Anna C. Pavlick, Lynn M. Schuchter, Rene Gonzalez, Grant A. McArthur
Journal of Clinical Oncology. 2013-05-10
Journal Articles
- Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based ImmunotherapyJonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine
- Pembrolizumab for Advanced Prostate Adenocarcinoma: Findings of the KEYNOTE-028 StudyM Gould, P Yang, P A Ott, Annals of Oncology
- A Cloning and Expression System to Probe T Cell Receptor Specificity and Assess Functional Avidity to NeoantigensWilliam J Lane, Patrick A Ott, Catherine J Wu, Donna E Leet, Blood
Press Mentions
Vaccine Slows Return of Pancreatic Cancer in Early TrialMay 11th, 2023- Pancreatic Cancer Vaccine Shows Promise in Small TrialMay 10th, 2023
- Experimental Cancer Vaccine Combined with Immunotherapy Delayed Return of Melanoma, Moderna and Merck SayApril 17th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
